Canadian Ebola vaccine to be tested in Europe, Gabon, Kenya
LONDON (Reuters) - Trials of an experimental vaccine developed by the Canadian government and licensed to NewLink Genetics will begin swiftly in healthy volunteers in Europe, Gabon and Kenya, under a program with funding from the Wellcome Trust.
Other threats on WHO's radar include Ebola and other high-threat pathogens, antimicrobial resistance, vaccine'hesitancy,'weak primary healthcare, and noncommunicable diseases.Medscape Medical News
Daily briefing: WHO calls out ‘vaccine hesitancy’ as top 10 health threatDaily briefing: WHO calls out ‘vaccine hesitancy’ as top 10 health threat, Published online: 16 January 2019; doi:10.1038/d41586-019-00188-9Anti-vaccination sentiment up there with deadly air pollution, Ebola and antibiotic resistance. Plus: the Milky Way is awesome and there’s a plant growing on the Moon.
[VOA] In northeastern Congo, more than 600 people have fallen ill with the Ebola virus, and at least 368 people have died from the disease. It's been difficult to contain the virus because of conflict in the region, despite medical advances, including a vaccine.
Publication date: Available online 10 January 2019Source: Journal of Theoretical BiologyAuthor(s): Sahil Jain, Manoj BaranwalAbstractComputational approach has shown remarkable progress in epitope mapping, paving the way to finding vaccine candidates against different viruses. In the current study, prediction algorithms and molecular docking were applied to select peptides containing multiple Ebola glycoprotein epitopes showing interaction with different HLA molecules. Six peptides containing overlapping multiple HLA I (CD8+) and II (CD4+) restricted T cell epitopes were generated via consensus approach applying six differ...
Scientists at The University of Texas Medical Branch said the drug could continue to protect people even as Ebola evolves. The efficiency could relieve burden on the frontline health care workers.
Scientists have developed a single dose treatment that has shown promise for combating the Ebola virus in tests with nonhuman primates and ferrets, a study says.
D, Pauly MH, Whaley KJ, Alter G, Walker LM, Chandran K, Zeitlin L, Qiu X, Geisbert TW, Dye JM Abstract Recent and ongoing outbreaks of Ebola virus disease (EVD) underscore the unpredictable nature of ebolavirus reemergence and the urgent need for antiviral treatments. Unfortunately, available experimental vaccines and immunotherapeutics are specific for a single member of the Ebolavirus genus, Ebola virus (EBOV), and ineffective against other ebolaviruses associated with EVD, including Sudan virus (SUDV) and Bundibugyo virus (BDBV). Here we show that MBP134AF, a pan-ebolavirus therapeutic comprising two broadly n...
(MedPage Today) -- Experts discuss how vaccination, experimental tx hope to control the epidemic
In the first episode for 2019, the TWiV team reviews the amazing virology stories of the past year. <span data-mce-type=”bookmark” style=”display: inline-block; width: 0px; overflow: hidden; line-height: 0;” class=”mce_SELRES_start”></span><span data-mce-type=”bookmark” style=”display: inline-block; width: 0px; overflow: hidden; line-height: 0;” class=”mce_SELRES_start”></span>&lt;span data-mce-type=”bookmark” style=”display: inline-block; width: 0px; overflow: […]
The response by WHO and partners to the ongoing Ebola virus disease (EVD) outbreak continues despite disruptions to key services due to security incidents taking place in Beni and Butembo during the recent election on 30 December 2018. In order to ensure the safety of all staff deployed, as a precautionary measure, operations were scaled back for a few hours on election day. All normal operations have been fully restored as of 1 January 2019. After an intensification of field activities in early December, notable improvements can be observed in many areas, notably a decrease in cases in Beni. However, hard-earned progress ...